Novacor upgrade
This article was originally published in The Gray Sheet
Executive Summary
WorldHeart will begin shipping an upgraded version of the left-ventricular assist device in the U.S. and Canada by the end of March, the company notes in a Jan. 7 release announcing FDA approval of the enhancements. Already approved in Canada and Europe, improvements include quieter pump operation, a smaller, longer-lasting battery and a smaller, quieter battery charger, according to the firm. Novacor is FDA-approved as a bridge to transplant, and will be the subject of a 250 to 300-patient destination therapy trial this year (1"The Gray Sheet" Nov. 10, 2003, p. 39)...
You may also be interested in...
WorldHeart Changes LVAD Development Plan, Cites Medicare Trial Coverage
WorldHeart likely will abandon efforts to earn FDA supplemental approval for the Novacor left-ventricular assist device as destination therapy based on results from the INTrEPID trial
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.